Pancreatic Cancer Drugs Market
Pancreatic Cancer Drugs Market Size, Share & Trends Analysis Report By Cancer Type (Exocrine, and Neuroendocrine Tumors (PNETs)), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration (Intravenous (IV), Oral), and Forecast Period (2026–2035)
Industry Overview
Pancreatic cancer drugs market was valued at $1.8 billion in 2025 and is projected to reach $3.5 billion by 2035, registering a CAGR of 7.0% from 2026 to 2035. Market growth is primarily driven by the rising incidence of pancreatic cancer, continuous advancements in targeted therapies, and the increasing adoption of combination treatment approaches. In November 2025, Pancreatic Cancer Action Network (PanCAN) reported that approximately 67,440 Americans are expected to be diagnosed with pancreatic cancer, with nearly 51,980 casualties annually, highlighting the severe disease burden. The organization also emphasized that pancreatic cancer remains one of the deadliest forms of cancer, with a five-year survival rate of around 13%. This alarming scenario underscores the urgent need for more effective and innovative treatment options, thereby accelerating demand within the pancreatic cancer drugs market. Additionally, rising healthcare expenditure and improving access to advanced oncology drugs are further contributing to market expansion.
Technological advancements and increasing research and development investments are significantly reshaping the treatment landscape. Innovations in immunotherapy and biomarker-driven therapies are enabling more personalized and effective treatment strategies. In November 2024, Merck & Co. announced the approval of WELIREG (belzutifan) in China for the treatment of patients with von Hippel–Lindau (VHL) disease-associated tumors, including pancreatic neuroendocrine tumors (pNETs). The therapy demonstrated strong clinical response rates, offering a promising targeted treatment option for patients with VHL-related conditions. This approval not only broadens available treatment options but also strengthens Merck’s position in the pancreatic cancer therapeutics space. Such developments reflect the growing emphasis on precision medicine and highlight the increasing pace of innovation and investment in the pancreatic cancer drugs market.
Market Dynamics
Precision Power: Targeted Therapies Drive the Next Wave of Pancreatic Cancer Innovation
Targeted therapy segment is witnessing rapid expansion, fueled by the growing adoption of precision medicine approaches that focus on specific genetic and molecular profiles of tumors. These therapies offer improved efficacy with reduced side effects compared to conventional treatments, making them increasingly preferred in pancreatic cancer care. In June 2024, IQVIA reported that the rising global incidence of cancer, along with a robust pipeline of innovative therapies, is significantly accelerating oncology drug development. The report projected that global cancer cases could reach nearly 32 million annually by 2050, highlighting the urgent need for advanced treatment solutions. Additionally, the increasing adoption of novel modalities such as biomarker-driven therapies and personalized medicine is reshaping treatment strategies. This trend is expected to further boost demand for targeted therapies, reinforcing their critical role in the growth of the pancreatic cancer drugs market.
Exocrine Pancreatic Cancer Dominates: High Prevalence Drives Market Demand
Exocrine pancreatic cancer segment holds the largest share of the pancreatic cancer drugs market, primarily due to its significantly higher prevalence compared to other types. It accounts for the majority of pancreatic cancer cases, making it the primary focus of diagnosis and treatment efforts. This dominance is largely attributed to the high incidence of pancreatic adenocarcinoma, the most common form of exocrine pancreatic cancer, which contributes to increased demand for effective therapeutic options. Additionally, ongoing advancements in chemotherapy, targeted therapies, and combination treatment approaches are further supporting the growth of this segment. As research continues to focus on improving survival outcomes, the exocrine segment is expected to maintain its leading position in the market.
Market Segmentation
- Based on cancer type, the market is segmented into exocrine and neuroendocrine tumors (PNETs).
- Based on therapy, the market is segmented into chemotherapy, targeted therapy, and immunotherapy.
- Based on route of administration, the market is segmented into intravenous (IV) and
IV Therapies Lead as Breakthrough Devices Transform Pancreatic Cancer Care
Intravenous administration continues to dominate the pancreatic cancer drugs market, primarily due to its widespread use in hospital-based chemotherapy protocols and its ability to deliver drugs effectively. This route remains the standard of care for advanced-stage treatment, ensuring controlled dosing and rapid therapeutic action. In February 2026, the , a first-of-its-kind wearable device for patients with locally advanced pancreatic cancer. Developed by Novocure, the device works in combination with chemotherapy by delivering tumour-treating electric fields that disrupt cancer cell division while sparing healthy tissues. Clinical studies demonstrated improved overall survival when used alongside standard chemotherapy regimens. This innovation represents a major step forward in integrating device-based therapies with traditional drug treatments. Together, these advancements highlight a shift toward more effective, multimodal approaches in pancreatic cancer care.
Regional Outlook
The global pancreatic cancer drugs market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading region in the market
North America continues to lead the pancreatic cancer drugs market, supported by its advanced healthcare infrastructure, strong presence of key pharmaceutical companies, and high adoption of innovative oncology treatments. The region also benefits from significant investments in research and development, along with early access to novel therapies and clinical trials. In March 2026, a clinical trial (NCT07259317) evaluated cabozantinib in patients with advanced neuroendocrine tumors, including pancreatic neuroendocrine tumors (pNETs). The study builds on earlier Phase 3 evidence demonstrating a significant improvement in progression-free survival compared to placebo, reinforcing its therapeutic potential. These findings highlight the expanding role of targeted therapies in pancreatic cancer treatment. Coupled with continuous clinical advancements and supportive regulatory frameworks, such developments are further strengthening North America’s leadership and driving innovation in the pancreatic cancer drugs market.
Market Players Outlook
The major companies operating in the global pancreatic cancer drugs market include Roche, Merck & Co., Pfizer, Novartis, and Bayer, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In February 2026, The US Food and Drug Administration (FDA) approved a wearable medical device used in combination with a standard chemotherapy regimen for the treatment of adult patients with locally advanced pancreatic cancer. The device, called Optune Pax, delivers a treatment called Tumor Treating Fields Therapy (TTFields).
- In February 2024, Ipsen announced that the US FDA approved its ONIVYDE (irinotecan liposome injection) regimen as a first-line treatment for metastatic pancreatic adenocarcinoma. The approval was based on Phase 3 NAPOLI 3 trial results demonstrating improved overall survival compared to standard chemotherapy. This marks a significant advancement and positions the ONIVYDE regimen as a potential new standard of care in the pancreatic cancer drug market.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global pancreatic cancer drugs market
- Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Pancreatic cancer drugs Market Sales Analysis – Cancer Type| Therapy | Route of Administration ($ Million)
- Pancreatic Cancer Drugs Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Pancreatic Cancer Drugs Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Pancreatic Cancer Drugs Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Pancreatic Cancer Drugs Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Pancreatic Cancer Drugs Market Revenue and Share by Manufacturers
- Pancreatic Cancer Drugs Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Roche Diagnostics
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bayer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Roche Diagnostics
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Pancreatic Cancer Drugs Market Sales Analysis By Cancer Type ($ Million)
- Exocrine Pancreatic Cancer
- Pancreatic Neuroendocrine Tumors (PNETs)
- Pancreatic Cancer Drugs Market Sales Analysis By Therapy ($ Million)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Pancreatic Cancer Drugs Market Sales Analysis By Route of Administration ($ Million)
- Intravenous
- Oral
- Regional Analysis
- North American Pancreatic Cancer Drugs Market Sales Analysis – Cancer Type| Therapy | Route of Administration| Country ($ Million)
- United States
- Canada
- North American Pancreatic Cancer Drugs Market Sales Analysis – Cancer Type| Therapy | Route of Administration| Country ($ Million)
- European Pancreatic Cancer Drugs Market Sales Analysis – Cancer Type| Therapy | Route of Administration | Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Pancreatic Cancer Drugs Market Sales Analysis – Cancer Type| Therapy | Route of Administration | Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Pancreatic Cancer Drugs Market Sales Analysis – Cancer Type | Therapy | Route of Administration| Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- Accord Healthcare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurobindo Pharma
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BeiGene
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Dr Reddy’s Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Exelixis
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fresenius Kabi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hikma Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ipsen
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mylan
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Accord Healthcare
1. Global Pancreatic cancer drugs Market Research and Analysis Cancer Type, 2025-2035 ($ Million)
2. Global Exocrine Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Pancreatic Neuroendocrine Tumors (PNETs) drugs Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Pancreatic Cancer Drugs Market Research and Analysis Therapy, 2025-2035 ($ Million)
5. Global Chemotherapy Drugs for Pancreatic Cancer Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Targeted Therapy for Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Immunotherapy for Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Pancreatic Cancer Drugs Market Research and Analysis Route of Administration 2025-2035 ($ Million)
9. Global Pancreatic Cancer Drugs for Intravenous Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Pancreatic Cancer Drugs for Oral Market Research and Analysis By Region, 2025-2035 ($ Million)
11. Global Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025-2035 ($ Million)
12. North American Pancreatic Cancer Drugs Market Research and Analysis By Country, 2025-2035 ($ Million)
13. North American Pancreatic Cancer Drugs Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
14. North American Pancreatic Cancer Drugs Market Research and Analysis By Therapy, 2025-2035 ($ Million)
15. North American Pancreatic Cancer Drugs Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
16. European Pancreatic Cancer Drugs Market Research and Analysis By Country, 2025-2035 ($ Million)
17. European Pancreatic Cancer Drugs Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
18. European Pancreatic Cancer Drugs Market Research and Analysis By Therapy, 2025-2035 ($ Million)
19. European Pancreatic Cancer Drugs Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
20. Asia-Pacific Pancreatic Cancer Drugs Market Research and Analysis By Country, 2025-2035 ($ Million)
21. Asia-Pacific Pancreatic Cancer Drugs Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
22. Asia-Pacific Pancreatic Cancer Drugs Market Research and Analysis By Therapy, 2025-2035 ($ Million)
23. Asia-Pacific Pancreatic Cancer Drugs Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
24. Rest of the World Pancreatic Cancer Drugs Market Research and Analysis By Country, 2025-2035 ($ Million)
25. Rest of the World Pancreatic Cancer Drugs Market Research and Analysis By Cancer Type, 2025-2035 ($ Million)
26. Rest of the World Pancreatic Cancer Drugs Market Research and Analysis By Therapy, 2025-2035 ($ Million)
27. Rest of the World Pancreatic Cancer Drugs Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
1. Global Pancreatic Cancer Drugs Market Research and Analysis Cancer Type, 2025 Vs 2035 ($ Million)
2. Global Exocrine Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
3. Global Pancreatic Neuroendocrine Tumors (PNETs) drugs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
4. Global Pancreatic cancer drugs Market Research and Analysis Therapy, 2025 Vs 2035 ($ Million)
5. Global Chemotherapy drugs for Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Targeted Therapy Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
7. Global Immunotherapy Pancreatic Cancer Drugs Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
8. Global Pancreatic Cancer Drugs Market Research and Analysis Route of Administration 2025 Vs 2035 ($ Million)
9. Global Pancreatic Cancer Drugs for Intravenous Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
10. Global Pancreatic Cancer Drugs for Oral Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
11. US Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
12. Canada Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
13. UK Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
14. France Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
15. Germany Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
16. Italy Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
17. Spain Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
18. Russia Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
19. Rest of Europe Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
20. India Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
21. China Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
22. Japan Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
23. South Korea Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
24. Australia and New Zealand Pancreatic Cancer Drugs Market Size, 2025-2035 ($ Million)
25. ASEAN Economies Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
26. Rest of Asia-Pacific Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
27. Latin America Pancreatic cancer drugs Market Size, 2025-2035 ($ Million)
28. Middle East and Africa Pancreatic Cancer Drugs Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
